Gamma-secretase modulators: a promising route for the treatment of Alzheimer's disease
Recent clinical data with three therapeutic anti-Aβ antibodies have demonstrated that removal of Aβ-amyloid plaques in early Alzheimer's disease (AD) can attenuate disease progression. This ground-breaking progress in AD medicine has validated both the amyloid cascade hypothesis and Aβ-amyloid...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Frontiers in Molecular Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnmol.2023.1279740/full |
| _version_ | 1797659619540074496 |
|---|---|
| author | Gunnar Nordvall Gunnar Nordvall Johan Lundkvist Johan Lundkvist Johan Lundkvist Johan Sandin Johan Sandin |
| author_facet | Gunnar Nordvall Gunnar Nordvall Johan Lundkvist Johan Lundkvist Johan Lundkvist Johan Sandin Johan Sandin |
| author_sort | Gunnar Nordvall |
| collection | DOAJ |
| description | Recent clinical data with three therapeutic anti-Aβ antibodies have demonstrated that removal of Aβ-amyloid plaques in early Alzheimer's disease (AD) can attenuate disease progression. This ground-breaking progress in AD medicine has validated both the amyloid cascade hypothesis and Aβ-amyloid as therapeutic targets. These results also strongly support therapeutic approaches that aim to reduce the production of amyloidogenic Aβ to prevent the formation of Aβ-pathology. One such strategy, so-called gamma-secretase modulators (GSM), has been thoroughly explored in preclinical settings but has yet to be fully tested in clinical trials. Recent scientific progress has shed new light on the role of Aβ in Alzheimer's disease and suggests that GSMs exhibit specific pharmacological features that hold great promise for the prevention and treatment of Alzheimer's disease. In this short review, we discuss the data that support why it is important to continue to progress in this class of compounds. |
| first_indexed | 2024-03-11T18:17:46Z |
| format | Article |
| id | doaj.art-02712783120143b5841629e85e753962 |
| institution | Directory Open Access Journal |
| issn | 1662-5099 |
| language | English |
| last_indexed | 2024-03-11T18:17:46Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Molecular Neuroscience |
| spelling | doaj.art-02712783120143b5841629e85e7539622023-10-16T04:43:38ZengFrontiers Media S.A.Frontiers in Molecular Neuroscience1662-50992023-10-011610.3389/fnmol.2023.12797401279740Gamma-secretase modulators: a promising route for the treatment of Alzheimer's diseaseGunnar Nordvall0Gunnar Nordvall1Johan Lundkvist2Johan Lundkvist3Johan Lundkvist4Johan Sandin5Johan Sandin6AlzeCure Pharma AB, Huddinge, SwedenDepartment of Neurobiology, Care Sciences, and Society, Division of Neurogeriatrics, Center for Alzheimer Research, Karolinska Institutet, Stockholm, SwedenAlzeCure Pharma AB, Huddinge, SwedenDepartment of Neurobiology, Care Sciences, and Society, Division of Neurogeriatrics, Center for Alzheimer Research, Karolinska Institutet, Stockholm, SwedenSinfonia Biotherapeutics AB, Huddinge, SwedenAlzeCure Pharma AB, Huddinge, SwedenDepartment of Neurobiology, Care Sciences, and Society, Division of Neurogeriatrics, Center for Alzheimer Research, Karolinska Institutet, Stockholm, SwedenRecent clinical data with three therapeutic anti-Aβ antibodies have demonstrated that removal of Aβ-amyloid plaques in early Alzheimer's disease (AD) can attenuate disease progression. This ground-breaking progress in AD medicine has validated both the amyloid cascade hypothesis and Aβ-amyloid as therapeutic targets. These results also strongly support therapeutic approaches that aim to reduce the production of amyloidogenic Aβ to prevent the formation of Aβ-pathology. One such strategy, so-called gamma-secretase modulators (GSM), has been thoroughly explored in preclinical settings but has yet to be fully tested in clinical trials. Recent scientific progress has shed new light on the role of Aβ in Alzheimer's disease and suggests that GSMs exhibit specific pharmacological features that hold great promise for the prevention and treatment of Alzheimer's disease. In this short review, we discuss the data that support why it is important to continue to progress in this class of compounds.https://www.frontiersin.org/articles/10.3389/fnmol.2023.1279740/fullgamma-secretasegamma-secretase modulatorGSMAlzheimer's diseaseAPPamyloid-beta |
| spellingShingle | Gunnar Nordvall Gunnar Nordvall Johan Lundkvist Johan Lundkvist Johan Lundkvist Johan Sandin Johan Sandin Gamma-secretase modulators: a promising route for the treatment of Alzheimer's disease Frontiers in Molecular Neuroscience gamma-secretase gamma-secretase modulator GSM Alzheimer's disease APP amyloid-beta |
| title | Gamma-secretase modulators: a promising route for the treatment of Alzheimer's disease |
| title_full | Gamma-secretase modulators: a promising route for the treatment of Alzheimer's disease |
| title_fullStr | Gamma-secretase modulators: a promising route for the treatment of Alzheimer's disease |
| title_full_unstemmed | Gamma-secretase modulators: a promising route for the treatment of Alzheimer's disease |
| title_short | Gamma-secretase modulators: a promising route for the treatment of Alzheimer's disease |
| title_sort | gamma secretase modulators a promising route for the treatment of alzheimer s disease |
| topic | gamma-secretase gamma-secretase modulator GSM Alzheimer's disease APP amyloid-beta |
| url | https://www.frontiersin.org/articles/10.3389/fnmol.2023.1279740/full |
| work_keys_str_mv | AT gunnarnordvall gammasecretasemodulatorsapromisingrouteforthetreatmentofalzheimersdisease AT gunnarnordvall gammasecretasemodulatorsapromisingrouteforthetreatmentofalzheimersdisease AT johanlundkvist gammasecretasemodulatorsapromisingrouteforthetreatmentofalzheimersdisease AT johanlundkvist gammasecretasemodulatorsapromisingrouteforthetreatmentofalzheimersdisease AT johanlundkvist gammasecretasemodulatorsapromisingrouteforthetreatmentofalzheimersdisease AT johansandin gammasecretasemodulatorsapromisingrouteforthetreatmentofalzheimersdisease AT johansandin gammasecretasemodulatorsapromisingrouteforthetreatmentofalzheimersdisease |